Lori J Goldstein MD

Oncology•Philadelphia, PA

Breast Cancer, Hematologic Oncology

Professor of Medicine, Temple University

Join to View Full Profile

333 Cottman Ave# FoxPhiladelphia, PA 19111
Phone+1 215-728-6900
Fax+1 215-728-3639

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
UPMC Medical EducationResidency, Internal Medicine, 1985 - 1986
UPMC Medical EducationResidency, Internal Medicine, 1982 - 1985
SUNY Upstate Medical UniversityClass of 1982
University of PennsylvaniaBA, Molecular Biology, Cum Laude; Brownlee Award, 1974 - 1978

Certifications & Licensure

PA State Medical License 1983 - 2024
MD State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2004-2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2011
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Join now to see all

Clinical Trials

Combination Chemotherapy in Treating Women With Breast Cancer Start of enrollment: 1998 Aug 20
Completed
Phase 3
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 3
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 2
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy Start of enrollment: 2005 Oct 07
Completed
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy Start of enrollment: 2011 Jan 03
Completed
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) Start of enrollment: 2012 Feb 27
Completed
Phase 1
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer Start of enrollment: 2017 Jun 13
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain
Journal of the National Cancer Institute. 2024-12-05
What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Emily Forester, Aakash Belsare, Dong Won Kim, Kristen Whitaker, Elias Obeid
The Journal of Surgical Research. 2024-07-01
202 citations
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2023-06-01

Journal Articles

In Support of CDK4/6 Inhibitors—A Meta-Analysis of Available Randomized Data
Lori Goldstein, MD, JAMA Network Open

Press Mentions

1 NCCN Guidelines for Patients® Inflammatory Breast Cancer, 2023March 23rd, 2023
Gene-Expression Profiling Raises Costs for Cancer Care Without Improving Outcomes for Low-Risk Breast Cancer Patients, According to ResearchersJanuary 22nd, 2019

Grant Support

Eastern Cooperative Oncology GroupNational Cancer Institute2003–2011
Development Of Breast Cancer Research Program At FcccNational Cancer Institute1994
Breast, Prostate, Ovarian And Cervical CancerNational Cancer Institute1993